Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215209 | 1.00 | AR (0.58) | ARSRD5A2SRD5A1 | |
| SCHEMBL5219041 | 0.91 | AR (0.54) | ARSRD5A2SRD5A1 | |
| SCHEMBL5219035 | 0.91 | AR (0.54) | ARSRD5A2SRD5A1 | |
| SCHEMBL5214108 | 0.89 | SRD5A1 (0.53) | ARSRD5A2SRD5A1 | |
| SCHEMBL5214096 | 0.89 | SRD5A1 (0.53) | ARSRD5A2SRD5A1 | |
| SCHEMBL5219057 | 0.89 | SRD5A1 (0.47) | ARSRD5A2SRD5A1 | |
| SCHEMBL5218386 | 0.88 | SRD5A1 (0.53) | ARSRD5A2SRD5A1 | |
| SCHEMBL5218391 | 0.88 | SRD5A1 (0.53) | ARSRD5A2SRD5A1 | |
| SCHEMBL5212380 | 0.86 | SRD5A1 (0.54) | SRD5A2SRD5A1 | |
| SCHEMBL5211550 | 0.86 | SRD5A1 (0.54) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | AR 1/4885SRD5A2 80/4885SRD5A1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.